文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

核脆性X智力障碍互作蛋白1对脓毒症树突状细胞凋亡的作用及调控机制

[Effect and regulatory mechanism of nuclear fragility X mental retardation interaction protein 1 on apoptosis of dendritic cells in sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2026-01-01
一句话结论小鼠实验中NUFIP1基因缺陷加重脓毒症早期脾树突状细胞凋亡、外周免疫抑制和多器官损伤,并降低7天生存率。

该研究构建Nufip1+/- C57BL/6J小鼠,以盲肠结扎穿孔(CLP)建立脓毒症模型,设假手术组与脓毒症组,24小时检测脾树突状细胞凋亡率、凋亡相关蛋白、血清细胞因子、多器官病理及7天生存率。结果:Nufip1+/-脓毒症组脾树突状细胞凋亡率43.41%±1.70%高于野生型脓毒症组30.43%±4.99%,caspase-3升高、Bcl-2降低,IL-2与IFN-γ降低而IL-4、IL-10、TGF-β升高,IFN-γ/IL-4比值降低,心、肺、肝、肾损伤更重,7天生存率20%(2/10)低于50%(5/10),内质网应激通路蛋白上调。结论提示NUFIP1基因缺陷通过内质网应激促进脓毒症早期脾树突状细胞广泛凋亡,加重外周免疫抑制与器官损伤。

要点

  • Nufip1+/-脓毒症小鼠24小时脾树突状细胞凋亡率43.41%±1.70%,高于野生型脓毒症组30.43%±4.99%(P<0.05)。
  • Nufip1+/-脓毒症组促炎因子IL-2(8.54±0.27 ng/L vs. 209.70±1.56 ng/L)与IFN-γ(391.60±9.24 ng/L vs. 512.70±31.50 ng/L)低于野生型脓毒症组。
  • Nufip1+/-脓毒症组抑炎因子IL-4、IL-10、TGF-β高于野生型脓毒症组,IFN-γ/IL-4比值降低(7.98±0.46 vs. 16.59±0.40),提示外周免疫抑制加重。
  • Nufip1+/-脓毒症组心、肺、肝、肾损伤较野生型脓毒症组更重,7天生存率20%(2/10)低于50%(5/10)(P<0.05)。
  • Nufip1+/-脓毒症组脾树突状细胞内质网应激通路HSPA5、p-EIF2AK3/EIF2AK3、p-EIF2A/EIF2A、ATF4、DDIT3表达上调,内质网形态改变更明显。

适用人群与场景

  • 动物实验:SPF级雄性野生型(WT)C57BL/6J小鼠与Nufip1+/- C57BL/6J小鼠,分为假手术组与脓毒症组。
  • 脓毒症模型采用盲肠结扎穿孔(CLP)建立;假手术组仅开腹并分离盲肠,不结扎。
  • 不涉及人类急诊或ICU患者,原文未提及临床适用人群。

诊断标准与关键阈值

  • 基因型验证:Western blotting显示Nufip1+/-小鼠脾树突状细胞NUFIP1/β-actin为1.080±0.233,低于WT小鼠2.178±0.440(P<0.05),提示基因敲除小鼠构建成功。
  • 脓毒症模型判定:CLP术后24小时取材检测;原文未提及临床诊断评分或阈值。

处置流程与药物剂量

  • 实验流程:CLP造模后24小时取眶血,处死后取心、肺、肝、肾及脾脏,分离脾树突状细胞。
  • 检测方法:流式细胞术测脾树突状细胞凋亡率;Western blotting测凋亡相关蛋白及内质网应激通路蛋白;ELISA测血清IL-2、IL-4、IL-10、TGF-β、IFN-γ;HE染色观察器官损伤;激光共聚焦显微镜观察内质网形态。
  • 生存分析:另取WT与Nufip1+/-小鼠各20只,分假手术组与脓毒症组各10只,观察CLP后7天生存率。

红旗征与不能漏的情况

  • 动物实验中Nufip1+/-脓毒症组出现更重的心、肺、肝、肾损伤及更低7天生存率(20% vs. 50%),提示NUFIP1缺陷与不良预后相关。

研究设计与关键结果

  • 研究类型:动物实验(基因敲除小鼠与野生型对照),样本量:48只用于24小时检测(假手术组18只、脓毒症组30只),另40只用于7天生存分析(每组各10只);单中心。
  • 脾树突状细胞凋亡率:Nufip1+/-脓毒症组43.41%±1.70% vs. WT脓毒症组30.43%±4.99%(P<0.05)。
  • 凋亡相关蛋白:Nufip1+/-脓毒症组caspase-3/β-actin 1.23±0.17高于WT脓毒症组0.59±0.14,Bcl-2/β-actin 0.46±0.13低于0.72±0.08(均P<0.05)。
  • 血清细胞因子:Nufip1+/-脓毒症组IL-2 8.54±0.27 ng/L低于WT脓毒症组209.70±1.56 ng/L,IFN-γ 391.60±9.24 ng/L低于512.70±31.50 ng/L;IL-4 73.19±2.38 ng/L高于28.52±0.98 ng/L,IL-10 359.20±2.02 ng/L高于267.60±5.05 ng/L,TGF-β 826.20±26.73 ng/L高于497.30±3.3
  • 器官损伤:HE染色示Nufip1+/-脓毒症组心、肺、肝、肾损伤较WT脓毒症组更重。
  • 7天生存率:Nufip1+/-脓毒症组20%(2/10)低于WT脓毒症组50%(5/10)(P<0.05)。
  • 内质网应激通路:Nufip1+/-脓毒症组脾树突状细胞HSPA5/β-actin 0.93±0.38高于WT脓毒症组0.34±0.02,p-EIF2AK3/EIF2AK3比值1.67±0.28高于0.59±0.05,p-EIF2A/EIF2A比值0.90±0.09高于0.61±0.08,ATF4/β-actin 1.71±0.77高于1.60±0.48,DDIT3/β-actin 1.18±0.12高于0.56±0.34(均P<0.05
  • 内质网形态:激光共聚焦显微镜示Nufip1+/-脓毒症组脾树突状细胞内质网形态改变更明显,呈不规则扭曲、肿胀和破碎。

证据类型、等级与局限

  • 证据类型:动物实验(基因敲除小鼠与野生型对照),非临床RCT或观察性研究。
  • 局限:单中心动物实验、样本量小(生存分析每组10只)、种属差异限制外推至人类;原文未报告盲法与样本量计算。

对床旁实践的改变

  • 原文为动物实验,不能直接改变急诊或ICU临床实践;不适用于人类患者决策。
  • 提示NUFIP1可能是脓毒症早期树突状细胞凋亡与免疫抑制的潜在机制靶点,但原文未提供任何临床干预或药物推荐。
  • 适用人群与不适用人群:仅适用于Nufip1+/-与野生型C57BL/6J小鼠CLP脓毒症模型,不适用于人类或其他动物模型。
  • 常见陷阱:不可将小鼠7天生存率20% vs. 50%或细胞因子数值外推为人类预后阈值或治疗目标。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the regulatory effect and mechanism of nuclear fragile X mental retardation-interacting protein 1 (NUFIP1) on the apoptosis of dendritic cells (DCs) in septic mice.

METHODS: Nufip1+/- C57BL/6J mice were generated, and Western blotting was performed to verify the protein expression level of NUFIP1 in splenic DCs. A total of 48 SPF male wild-type (WT) mice and Nufip1+/- mice were divided into the sham group (18 mice) and the sepsis group (30 mice). Three independent replicate experiments were conducted, and mice were grouped using a random number table in each trial. The cecal ligation and puncture (CLP) procedure was performed to establish the sepsis model in the sepsis group; mice in the Sham group only underwent laparotomy and cecal separation without ligation. Twenty-four hours after operation, orbital blood was collected. The mice were then sacrificed, and heart, lung, liver, kidney tissues as well as spleens were harvested for isolation and extraction of splenic DCs. Flow cytometry was applied to detect the apoptosis rate of splenic DCs. Western blotting was used to determine the protein expression levels of apoptosis-related proteins including caspase-3, Bcl-2, heat shock protein 5 (HSPA5), eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3), phosphorylated EIF2AK3 (p-EIF2AK3), eukaryotic translation initiation factor 2A (EIF2A), phosphorylated EIF2A (p-EIF2A), activating transcription factor 4 (ATF4) and DNA damage-inducible transcript 3 protein (DDIT3) in splenic DCs. Enzyme-linked immunosorbent assay (ELISA) was adopted to detect the serum levels of interleukins (IL-2, IL-4, IL-10), transforming growth factor-β (TGF-β) and interferon-γ (IFN-γ). Hematoxylin-eosin (HE) staining was performed to observe the injury of heart, lung, liver and kidney under light microscope. The endoplasmic reticulum (ER) morphology of splenic DCs was observed under a laser confocal microscope. An additional 20 WT mice and 20 Nufip1+/- mice were respectively assigned to the sham group and sepsis group, with 10 animals in each subgroup. The 7-day survival rate after CLP was observed in all groups.

RESULTS: Western blotting results showed that the protein expression level of NUFIP1 in splenic DCs of Nufip1+/- mice was lower than that of WT mice (NUFIP1/β-actin: 1.080±0.233 vs. 2.178±0.440, P<0.05), indicating the successful construction of NUFIP1 gene-deficient mice. Flow cytometry results revealed that the apoptosis rate of splenic DCs at 24 h after CLP in the Nufip1+/- sepsis group was higher than that in the WT sepsis group [(43.41±1.70)% vs. (30.43±4.99)%, P<0.05]. Meanwhile, compared with the WT sepsis group, the protein expression level of caspase-3 in splenic DCs was increased, while the protein expression level of Bcl-2 was decreased in the Nufip1+/- sepsis group (caspase-3/β-actin: 1.23±0.17 vs. 0.59±0.14, Bcl-2/β-actin: 0.46±0.13 vs. 0.72±0.08, all P<0.05). Compared with the WT sepsis group, the serum levels of IL-2 and IFN-γ in the Nufip1+/- sepsis group were decreased [IL-2 (ng/L): 8.54±0.27 vs. 209.70±1.56; IFN-γ (ng/L): 391.60±9.24 vs. 512.70±31.50, all P<0.05], whereas the serum levels of IL-4, IL-10 and TGF-β were increased [IL-4 (ng/L): 73.19±2.38 vs. 28.52±0.98; IL-10 (ng/L): 359.20±2.02 vs. 267.60±5.05; TGF-β (ng/L): 826.20±26.73 vs. 497.30±3.33, all P<0.05], and the IFN-γ/IL-4 ratio was decreased (7.98±0.46 vs. 16.59±0.40, P<0.05). These findings suggested that peripheral immunosuppression was further aggravated in Nufip1+/- mice during sepsis relative to WT mice. HE staining demonstrated that the injury of heart, lung, liver, kidney and other tissues in the Nufip1+/- sepsis group was markedly severer than that in the WT sepsis group, and the 7-day survival rate was lower in Nufip1+/- mice [20% (2/10) vs. 50% (5/10), P<0.05). Compared with the WT sepsis group, the protein expression levels of HSPA5, the ratio of p-EIF2AK3 to EIF2AK3, the ratio of p-EIF2A to EIF2A, ATF4 and DDIT3 in splenic DCs after CLP were all up-regulated in the Nufip1+/- sepsis group (HSPA5/β-actin: 0.93±0.38 vs. 0.34±0.02, p-EIF2AK3/EIF2AK3 ratio: 1.67±0.28 vs. 0.59±0.05, p-EIF2A/EIF2A ratio: 0.90±0.09 vs. 0.61±0.08, ATF4/β-actin: 1.71±0.77 vs. 1.60±0.48, DDIT3/β-actin: 1.18±0.12 vs. 0.56±0.34, all P<0.05). Laser confocal microscopy showed that the morphological changes of ER in splenic DCs of the Nufip1+/- sepsis group were more obvious than those in the WT sepsis group, presenting irregular distortion, swelling and fragmentation.

CONCLUSIONS: NUFIP1 gene deficiency induces extensive apoptosis of splenic DCs in the early stage of sepsis, further aggravate peripheral immunosuppression, exacerbate multiple organ damage and worsen survival outcomes in septic animals.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zheng L, Yao R, Dong N, et al. [Effect and regulatory mechanism of nuclear fragility X mental retardation interaction protein 1 on apoptosis of dendritic cells in sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42427322. doi:10.3760/cma.j.cn121430-20251022-00521

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。